Immuneering Corp
IMRX
NASDAQ
Biotechnology
$5.06
USD
-0.14 (-2.69%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $336.43M
Volume 523.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-57.28M
TTM
+7.8%
YoY
Operating Cash Flow
$-56.75M
TTM
-10.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.3 | 4.5 | 4.5 | 4.7 | 5.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 14.8 | 15.4 | 13.8 | 15.3 | 19.0 |
Operating Income | -14.8 | -15.4 | -13.8 | -15.3 | -19.0 |
EBITDA | -14.7 | -15.3 | -13.7 | -15.2 | -18.9 |
Other Income / Expense | 0.0 | 0.0 | 0.3 | 0.5 | 0.6 |
Total Other Income / Expense | 0.3 | 0.4 | 2.2 | 1.9 | 1.7 |
Income Before Income Taxes | -14.4 | -15.0 | -11.6 | -13.5 | -17.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -14.4 | -15.0 | -11.6 | -13.5 | -17.3 |
Consolidated Net Income / Loss | -14.4 | -15.0 | -11.6 | -13.5 | -17.3 |
Net Income Attributable to Common Shareholders | -14.4 | -15.0 | -11.6 | -13.5 | -17.3 |
Basic EPS | -$0.40 | -$0.38 | -$0.18 | -$0.21 | -$0.27 |
Diluted EPS | -$0.40 | -$0.38 | -$0.18 | -$0.21 | -$0.27 |
Basic Shares Outstanding | 36.0M | 39.7M | 64.9M | 64.7M | 64.7M |
Diluted Shares Outstanding | 36.0M | 39.7M | 64.9M | 64.7M | 64.7M |